Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic MalignanciesNina Shah, Krina K. Patel, Zachary Lee et al.|Future Oncology|2021Cited by 21
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic MalignanciesNina Shah, Krina K. Patel, Alan Tan et al.|Blood|2021Cited by 4
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignanciesNina Shah, Krina K. Patel, Alan Tan et al.|Regular and Young Investigator Award Abstracts|2020Cited by 3
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic MalignanciesKrina K. Patel, Miguel‐Angel Perales, Nina Shah et al.|Blood|2022Cited by 0